Structure Therapeutics (GPCR) investor relations material

Executive summary

• Clinical-stage biopharma focused on oral small molecule therapeutics for chronic diseases, leveraging structure-based drug discovery and computational chemistry expertise.

• Lead candidate aleniglipron (oral GLP-1R agonist) showed up to 16.3% placebo-adjusted mean weight loss at 44 weeks in Phase 2, the highest efficacy among oral GLP-1RAs and comparable to injectables.

• Received positive end-of-Phase 2 FDA feedback, with Phase 3 initiation for aleniglipron on track for Q3 2026.

• Pipeline includes amylin receptor agonists (ACCG-2671, ACCG-3535), GIPR/GCGR programs, and LPA1R antagonist for IPF, with ACCG-2671 entering Phase 1 and ACCG-3535 to start Phase 1 in Q4 2026.

• Cash, cash equivalents, and short-term investments totaled $1.5 billion as of March 31, 2026, providing runway through 2028.

Financial highlights

• Cash, cash equivalents, and short-term investments were $1.5 billion as of March 31, 2026.

• Net loss for Q1 2026 was $76.0 million, up from $46.8 million in Q1 2025, driven by increased R&D and G&A expenses.

• Research and development expenses rose to $66.5 million in Q1 2026 from $42.9 million in Q1 2025; G&A expenses increased to $22.9 million from $13.4 million.

• Interest and other income, net, increased to $13.6 million due to higher investment balances.

• Net cash provided by operating activities was $15.2 million, with significant investing outflows due to purchases of short-term investments.

Outlook and guidance

• Existing cash and investments expected to fund operations and key clinical milestones through end of 2028, including Phase 3 aleniglipron program.

• Topline results from ongoing aleniglipron studies (ACCESS OLE and Body Composition) expected in Q3 and Q4 2026; Phase 3 initiation planned for Q3 2026.

• Phase 1 data for ACCG-2671 expected in 2H 2026; Phase 1 for ACCG-3535 to start in Q4 2026.

• Expects continued increase in R&D and G&A expenses as pipeline advances and company grows.